普卢利沙星3种晶型的制备、表征与稳定性研究

doi:10.19803/j.1672-8629.20230093

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (4): 374-378.
DOI: 10.19803/j.1672-8629.20230093

• 前沿分析方法在药品质量评价中的应用专栏 • 上一篇下一篇

普卢利沙星3种晶型的制备、表征与稳定性研究

黄茵茵¹, 张立雯^1,*, 刘静¹, 陈静¹, 周远华¹, 许明哲², 姚尚辰^2#, 王晨², 张现化³

¹广州市药品检验所,广东广州 510160;
²中国食品药品检定研究院,北京 102629;
³北京大学第三医院药剂科,北京 100191

收稿日期:2023-02-23 出版日期:2023-04-15 发布日期:2023-04-20
通讯作者: ^*张立雯,女,主任药师,药品质量标准。E-mail：mwener@126.com;^#为共同通信作者。
作者简介:黄茵茵,女,药师,药品质量标准与药品化妆品检验。
基金资助:
国家重点研发计划（SQ2022YFC3401205）; 广州市科技计划项目（202102080660）

Preparation, characterization and stability of three forms of prulifloxacin

HUANG Yinyin¹, ZHANG Liwen^1,*, LIU Jing¹, CHEN Jing¹, ZHOU Yuanhua¹, XU Mingzhe², YAO Shangchen^2#, WANG Chen², ZHANG Xianhua³

¹Guangzhou Institute for Drug Control, Guangzhou Guangdong 510160, China;
²National Institutes for Food and Drug Control, Beijing 102629, China;
³Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China

Received:2023-02-23 Online:2023-04-15 Published:2023-04-20

摘要/Abstract

摘要： 目的研究普卢利沙星的多晶型特征,为该药晶型杂质成分的质量控制提供科学依据。方法制备了普卢利沙星的3种晶型（晶型Ⅰ、晶型Ⅱ和晶型Ⅲ）,采用粉末X射线衍射法、红外光谱法、差示扫描量热分析、拉曼光谱法对普卢利沙星3种晶型进行了表征分析,并通过混悬实验探索3种晶型之间的转化规律及稳定性关系。结果粉末X射线衍射法、红外光谱法、差示扫描量热分析、拉曼光谱法均能有效区分普卢利沙星的3种晶型,晶型间的稳定性关系为晶型Ⅰ>晶型Ⅱ>晶型Ⅲ。结论本实验建立的分析方法为普卢利沙星晶型控制标准的制定提供依据。

关键词: 普卢利沙星, 多晶型, 表征, 稳定性, 粉末X射线衍射法, 红外光谱法, 差示扫描量热分析, 拉曼光谱法

Abstract: Objective To study the polymorphism of prulifloxacin and provide a scientific basis for the quality control of the polymorphic impurities in the drug. Methods Three forms of prulifloxacin (formⅠ, formⅡ and form Ⅲ) were prepared. The forms were characterized by using powder X-ray diffraction, infrared spectroscopy, differential scanning calorimetry and Raman spectroscopy, and the stability relationship and crystal transformation rules of the three forms were explored by suspension experiments. Results Powder X-ray diffraction, infrared spectroscopy, thermal analysis and Raman spectroscopy were used to identify the three polymorphs of prulifloxacin effectively. The stability relationship of forms is: formⅠ> formⅡ > form Ⅲ. Conclusion This study provides references for the formulation of the standard of prulifloxacin.

Key words: prulifloxacin, polymorphism, characterization, stability, powder X-ray diffraction, infrared spectroscopy, differential scanning calorimetry, Raman spectroscopy

中图分类号:

R917

黄茵茵, 张立雯, 刘静, 陈静, 周远华, 许明哲, 姚尚辰, 王晨, 张现化. 普卢利沙星3种晶型的制备、表征与稳定性研究[J]. 中国药物警戒, 2023, 20(4): 374-378.

HUANG Yinyin, ZHANG Liwen, LIU Jing, CHEN Jing, ZHOU Yuanhua, XU Mingzhe, YAO Shangchen, WANG Chen, ZHANG Xianhua. Preparation, characterization and stability of three forms of prulifloxacin[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 374-378.

参考文献

[1] ZHANG JJ, QIAN S, GAO Y.Theory and Practice of Polymorphic Drug Development(晶型药物研发理论与应用)[M]. Beijing: Chemical Industry Press, 2019.
[2] JIN ZH, GU JJ, ZHENG ML, et al.The determination and evaluation methods of drug polymorphism[J]. China Pharmacy(中国药房), 2016, 27(30): 4318-4320.
[3] HAO TH, LIU H, CHEN CQ.Advances in study on influence of crystal transformation on drug stability[J]. Drugs & Clinic(现代药物与临床), 2013, 28(3): 457-460.
[4] MA LW, DU W, ZHAO CS.Advances in the quantitative analytical methods of drug polymorphism[J]. Acta Pharmaceutica Sinica(药学学报), 2011, 46(8): 896-903.
[5] LYU RQ, XI YB, LYU JL, et al.Advances in the fourth-generation fluoroquinolone antibacterial agents[J]. Chinese Journal of New Drugs(中国新药杂志), 2012, 21(13): 1485-1493.
[6] SU W.Progress in clinical research of prulifloxacin[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2013, 2(7): 394-396.
[7] WANG JY, WANG JX, LIU ML.Advances in clinical research of prulifloxacin in the treatment of other systemic infections[J]. World Notes on Antibiotics(国外医药抗生素分册), 2011, 32(5): 205-210.
[8] TANG HJ, CHEN DW.Optimization of formula for prulifloxacin dispersible tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015,12(2): 86-88.
[9] MORAMPUDI R, MOHAMMAD SA, MOHAN P, et al.Pharmaceutical cocrystal of prulifloxacin with nicotinamide[J]. International Journal of Pharmacy and Pharmaceutical Sciences, 2014, 6(10): 180-184.
[10] SHARMA TK, KANAWADE ST. Process for the preparation of crystals of prulifloxacin: PCT, WO2008/111018 A9[P]. 2008-09-18.
[11] NIMBALKAR M, KHATRI N, BHAYANI PJ, et al. Process for the preparation of typeⅠ, typeⅡand type Ⅲ crystalline prulifloxacin: PCT, WO2010/084508 A2[P]. 2010-07-29.
[12] XIAO Y, WANG JK, YIN QX, et al.Quantitative analyzing methods for polymorphism of pharmaceuticals[J]. Petrochemical Technology(石油化工), 2015, 44(1): 11-18.
[13] YANG SY, XING C, ZHANG L, et al.Qualitative detection for polymorphs in solid pharmaceutical preparations by powder X ray diffraction[J]. Herald of Medicin(医药导报), 2015, 34(7): 930-934.
[14] YANG SY, ZHANG L, DU GH, et al.Quantitative analysis of nitrendipine polymorph using differential scanning calorimetry[J]. Chinese Journal of New Drugs(中国新药杂志), 2015, 24(12): 1423-1434.
[15] YE XX, LIU Q, GENG ZW, et al.Determination of lamivudine monomorphic form I by raman spectroscopy[J]. Chinese Journal of Pharmaceuticals(中国医药工业杂志), 2013, 44(1): 60-63.

普卢利沙星3种晶型的制备、表征与稳定性研究

Preparation, characterization and stability of three forms of prulifloxacin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾茵茵, 张财树, 周颖, 刘丽, 耿颖, 魏宁漪, 钮思静, 陈华, 许卉. 吸入制剂微细粒子空气动力学粒径分布评价方法研究[J]. 中国药物警戒, 2024, 21(2): 141-146.
[2]	耿颖, 刘毅, 王雪蕾, 谭德讲, 朱容蝶, 郭贤辉, 陈华, 郑丽娥. 近红外光谱法和统计学过程控制方法对亚叶酸钙药品对照品水分进行质量控制的研究[J]. 中国药物警戒, 2023, 20(11): 1221-1227.
[3]	熊婧, 戴霞林, 何兰, 武香香. 药物共晶表征方法研究进展[J]. 中国药物警戒, 2021, 18(10): 995-999.
[4]	钱佩佩, 曹凯, 赵亮, 兰为民, 兰丙欣. 药品有效期和使用期限的探讨[J]. 中国药物警戒, 2018, 15(7): 414-418.
[5]	周明霞, 高会芹, 彭雄颖, 李亚涛, 李军山, 屈云萍, 李振江. 地黄不同炮制品配方颗粒的红外快速鉴别[J]. 中国药物警戒, 2017, 14(2): 87-89.
[6]	侯文洁, 丁红梓, 周秋云, 王洁. 注射用利福平在6种溶媒中的稳定性考察[J]. 中国药物警戒, 2016, 13(8): 500-502.
[7]	张敬一, 刘阳, 刘美彤, 高声传. 棓丙酯注射液与不同输液配伍的稳定性研究[J]. 中国药物警戒, 2016, 13(8): 496-499.
[8]	林小明,黄敏,谢培德. 注射用硝普钠与氯化钠注射液配伍后使用时间延长至26 小时的临床研究[J]. 中国药物警戒, 2016, 13(5): 298-302.
[9]	高声传,王童超. 血必净注射液与多种溶媒配伍的稳定性研究[J]. 中国药物警戒, 2016, 13(3): 180-182.
[10]	邓建华, 杨红, 王福东. 他扎罗汀乳膏的制备及稳定性考察[J]. 中国药物警戒, 2016, 13(3): 146-147.
[11]	李青松. 溶媒种类对埃索美拉唑联合其他药物时稳定性的影响[J]. 中国药物警戒, 2016, 13(10): 623-626.
[12]	郝好华,宋金春,杨小青,谢顺岚. 注射用五水头孢唑林钠与替硝唑体外配伍稳定性研究[J]. 中国药物警戒, 2015, 12(6): 368-372.
[13]	唐洪娟,陈大为. 普卢利沙星分散片处方筛选[J]. 中国药物警戒, 2015, 12(2): 86-88.
[14]	林小明, 韦宝含, 曾毅, 韦平原, 梁汉钦, 谢伟乾, 陈明忠. 注射用硝普钠在氯化钠注射液中稳定性研究[J]. 中国药物警戒, 2014, 11(6): 369-372.
[15]	王艳春, 李旭东, 刘莹, 冯影. 舒血宁注射液溶媒配伍研究[J]. 中国药物警戒, 2014, 11(5): 309-311.